DUPIXENT specifically targets the IL-4α receptor in severe asthma1–3
The interleukins; IL-4 and IL-13, are important in the development of Type 2 inflammation and its downstream effects in severe asthma2–7
DUPIXENT is a fully human monoclonal antibody for administration by subcutaneous injecton1
DUPIXENT inhibits IL-4 and IL-13 signalling1,2
Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131–4
Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41–4
Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131–4
Inhibition of IL-4 and IL-13 markedly decreases:1,2
Fractional exhaled nitric oxide (FeNO), a marker
of IL-13 related to lung inflammation
- Sanofi Genzyme. Dupixent Summary of Product Characteristics, September 2021.
- Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
- Krings JG, et al. J Allergy Clin Immunol Pract. 2019;7(5):1379–1392.
- Doran E, et al. Front Med. 2017;4:139.
- Tran TN, et al. Ann Allergy Asthma Immunol. 2016;116(1):37–42.
- Seys SF, et al. Respir Res. 2017;18:39.
- Peters MC, et al. J Allergy Clin Immunol. 2014;133(2):388–394.
FeNO, fractional exhaled nitric oxide; IgE, Immunoglobulin E; IL, interleukin; R, receptor; γC, gamma C subunit.
MAT-GB-2004974(v4.0) | Date of preparation: February 2022